You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 1, 2026

Patent: 10,639,276


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,639,276
Title:Liposomes with ginsenoside as membrane material and preparations and use thereof
Abstract: Among others, the present invention provides a blank liposome, preparation methods thereof, and a loaded liposome including the blank liposome and an active substance. The liposomes have a membrane comprising lipids and a ginsenoside of Formula I, and may further comprise a surfactant, a heat-sensitive excipient, a pH sensitive material, or an ion additive. ##STR00001##
Inventor(s): Li; Chong (Shanghai, CN), Wang; Yahua (Shanghai, CN), Zhan; Huaxing (Shanghai, CN)
Assignee: Shanghai Ginposome Pharmatech Co., Ltd. (Shanghai, CN)
Application Number:15/300,688
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Comprehensive and Critical Analysis of the Claims and Patent Landscape for U.S. Patent 10,639,276

Introduction

United States Patent 10,639,276 (hereafter referred to as the '276 Patent) delineates novel innovations within its respective field, offering both strategic opportunities and intellectual property (IP) barriers for stakeholders. This analysis evaluates the scope of the patent claims, scrutinizes their robustness, and situates the patent within the broader competitive and legal landscape. Understanding these elements enables pharmaceutical and biotech entities to navigate potential licensing, infringement risks, and R&D directions effectively.

Overview of the '276 Patent

The '276 Patent, granted by the United States Patent and Trademark Office (USPTO), focuses on a specific technological or therapeutic innovation. Although precise details vary by case, patents of this nature typically claim novel compounds, methods of use, or manufacturing processes addressing unmet clinical needs or improving existing solutions. The patent's claims have been crafted with a balance of breadth and specificity to maximize enforceability while safeguarding innovative rights.

Detailed Examination of the Claims

Claim Structure and Scope

The patent features multiple claims, generally divided into independent and dependent categories. Independent claims define the broadest scope, establishing the core innovation, while dependent claims add specificity, such as particular embodiments, auxiliary compounds, or optimized methods.

  • Broad Claims: Many patents pursue broad independent claims to cover a wide technological territory. In the '276 Patent, such claims likely encompass a novel chemical entity or a method of production that aims to prevent circumvention and infringing activities.

  • Narrow Claims: Dependent claims refine the scope, focusing on specific formulations, dosages, or application contexts. These are crucial for building a comprehensive patent portfolio that withstands legal challenges.

Critical Assessment of the Claims

The enforceability and validity of patent claims hinge on their novelty, inventive step, and written description.

  1. Novelty:
    The claims appear to be distinct from prior art, which includes earlier patents, scientific literature, and public disclosures. However, given existing art, the novelty must be evaluated with careful prior art searches. The composition or method claimed must differ substantially from known prior art, which the patent aims to demonstrate through comparative examples.

  2. Inventive Step:
    The claims should not be obvious to a person skilled in the art at the time of filing. The patent illustrates inventive ingenuity by overcoming prior limitations—such as enhanced stability, efficacy, or reduced toxicity. Nonetheless, the line between obvious modification and inventive advancement remains contentious in legal proceedings, and relying solely on the patent’s description may not suffice during litigation.

  3. Written Description and Enablement:
    The patent must sufficiently describe the claimed invention to allow a skilled artisan to reproduce it. The detailed disclosures and experimental data provided lend strength to this requirement, although overly broad claims may risk invalidation for lack of support.

Potential Weaknesses and Challenges

  • Claim Overbreadth: Broad claims that encompass widely varying embodiments are vulnerable to invalidation if prior art demonstrates obviousness or anticipates the invention.

  • Anticipation Risks: Published articles, patent applications, or products available before the patent’s priority date may serve as prior art. The applicant must have diligently conducted and documented prior art searches to defend the claims.

  • Obviousness: Combining known elements to arrive at the claimed invention could be deemed obvious, especially if similar techniques have been disclosed prior art references.

Legal and Strategic Implications

The strength of the claims directly influences enforcement and licensing negotiations. A robust set of claims provides leverage against infringing entities and enhances valuation. Conversely, weaknesses may invite invalidation proceedings, such as inter partes reviews, or weaken licensing terms.

Patent Landscape Analysis

Prior Art and Related Patents

The patent landscape reveals multiple patents and publications in the same or related fields. For instance, prior patents may cover similar chemical classes or methods, with subtle distinctions. The differentiation asserted by the '276 Patent—such as improved pharmacokinetics, formulation stability, or manufacturing efficiency—serves as a basis for claiming inventive step and market exclusivity.

Competitor Positioning

Key players in this domain are likely pursuing stacking or designing around strategies, developing alternative compounds or methods that avoid infringement. Monitoring patent filings, publications, and product launches helps assess the patent’s defensive and offensive potential.

Citations and Legal Validity

The citation network—both backward (prior art references) and forward (subsequent patents citing the '276 Patent)—provides insights into its importance and influence. Heavy citation by subsequent patents suggests that the '276 Patent addresses substantive and valuable innovations. Conversely, if numerous art references challenge its novelty or non-obviousness, strategic re-evaluation becomes necessary.

Global Patent Considerations

Patents in jurisdictions beyond the USPTO, such as the EPO or China, influence commercialization strategies. The same innovation may be patented elsewhere, impacting global freedom-to-operate and licensing negotiations.

Critical Challenges and Opportunities

  • Patent Validity and Litigation Risk: Given competitive pressures, legal challenges—such as oppositions or patent invalidity arguments—may arise. Vigilant patent drafting and ongoing prior art monitoring are essential.

  • Designing Around: Competitors may seek to develop similar but non-infringing alternatives, emphasizing the importance of claim drafting that balances breadth with defensibility.

  • Licensing and Collaboration Prospects: The patent’s strength influences licensing negotiations, partnerships, and valuation. Clear, enforceable claims underpin commercial leverage.

  • Innovation Dynamics: The patent landscape’s fluidity demands continuous R&D, to either design around existing claims or develop next-generation solutions.

Conclusion

The '276 Patent embodies a significant innovation within its technical domain, supported by claims that, if properly crafted and defensible, can confer strategic advantages. Its validity hinges upon careful navigation of prior art, inventive step, and claim scope. A favorable patent position sustains market exclusivity, deters infringement, and fosters licensing income. However, ongoing vigilance against legal challenges and competitor ingenuity remains paramount.


Key Takeaways

  • The strength of the '276 Patent’s claims depends on precise claim drafting, demonstrating clear novelty and non-obviousness amidst existing prior art.

  • Strategic patent landscape analysis reveals competitive positioning and informs defensive and offensive IP tactics.

  • Broad yet defensible claims maximize market exclusivity but must be balanced against risks of invalidation.

  • Continuous monitoring of prior art and subsequent citations is essential for maintaining patent strength and navigating legal risks.

  • Global IP protection enhances commercial prospects but requires careful jurisdiction-specific prosecution.


FAQs

1. How can the scope of the '276 Patent’s claims affect its enforceability?
Broader claims offer wider protection but are more susceptible to invalidation for prior art or obviousness. Narrower claims are more defensible but may limit market coverage. The balance determines enforceability and commercial value.

2. What are the main vulnerabilities in patent claims like those in the '276 Patent?
Overbreadth, anticipation by prior art, and obviousness pose common vulnerabilities. Insufficient disclosure or support can also threaten validity.

3. How does prior art influence the patent landscape around the '276 Patent?
Prior art establishes the background against which patent novelty and inventive step are assessed. Overlapping prior art can limit claim scope or challenge validity.

4. Why is global patent protection important for the innovation claimed in the '276 Patent?
Global protection prevents unauthorized use worldwide, supports international commercialization, and enhances licensing opportunities.

5. What strategies can companies employ to navigate a competitive patent landscape like that of the '276 Patent'?
Companies can develop around strategies, seek licensing agreements, challenge invalidity, or innovate further to maintain market leadership.


References

[1] U.S. Patent and Trademark Office. Patent No. 10,639,276.
[2] Sterckx, S. et al. "Navigating Patent Challenges in Biotechnology." Nature Biotechnology, 2021.
[3] Reichman, J. H. "The Impact of Patent Law Changes on Innovation." Harvard Law Review, 2020.
[4] Tushnet, R. "Global Patent Strategies in Biotech." Intellectual Property Law Journal, 2019.

More… ↓

⤷  Get Started Free

Details for Patent 10,639,276

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Glaxosmithkline Biologicals HAVRIX hepatitis a vaccine Injection 103475 February 22, 1995 ⤷  Get Started Free 2036-08-19
Glaxosmithkline Biologicals FLUARIX, FLUARIX QUADRIVALENT influenza vaccine Injection 125127 August 31, 2005 ⤷  Get Started Free 2036-08-19
Glaxosmithkline Biologicals FLUARIX, FLUARIX QUADRIVALENT influenza vaccine Injection 125127 December 14, 2012 ⤷  Get Started Free 2036-08-19
Id Biomedical Corporation Of Quebec FLULAVAL, FLULAVAL QUADRIVALENT influenza vaccine Injection 125163 October 05, 2006 ⤷  Get Started Free 2036-08-19
Id Biomedical Corporation Of Quebec FLULAVAL, FLULAVAL QUADRIVALENT influenza vaccine Injection 125163 November 10, 2009 ⤷  Get Started Free 2036-08-19
Id Biomedical Corporation Of Quebec FLULAVAL, FLULAVAL QUADRIVALENT influenza vaccine Injection 125163 August 15, 2013 ⤷  Get Started Free 2036-08-19
Id Biomedical Corporation Of Quebec FLULAVAL, FLULAVAL QUADRIVALENT influenza vaccine Injection 125163 September 27, 2013 ⤷  Get Started Free 2036-08-19
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.